Teva Pharmaceutical Industries Ltd. (TEVA), the world’s biggest generic-drug company, may have sold 14 million pounds ($22.5 million) of its generic version of Pfizer Inc. (PFE)’s anti-cholesterol drug Lipitor last month, although the patent doesn’t expire until next year, the Financial Times reported, citing unidentified industry analysts.
Teva is estimated to have shipped up to 700,000 packets of the medicine to the U.K. to be sold at a discount of at least 15 percent to the previous trade price, the FT said. Pfizer sought and won a High Court injunction last week to stop further sales of Teva’s version of the drug, the FT said.
A call to the company’s corporate communications manager, Shir Altay-Hagoel, out of office hours went unanswered.
No comments:
Post a Comment